Management of Idiopathic Pulmonary Fibrosis in the Elderly Patient [ CHEST JULY 2015 ] 호흡기내과 R4. 박세정.

Slides:

Advertisements

Similar presentations

Charlotte Carlson, MD, MPH Clinical Geriatrics Fellow University of California at San Francisco AAHCM Annual Meeting, May 14, 2014, Orlando, FL ©AAHCM.

Advertisements

IPF MANAGEMENT: WHAT DO WE DO NOW? Steven A. Sahn, MD Professor of Medicine and Director Division of Pulmonary, Critical Care, Allergy and Sleep Medicine.

Idiopathic pulmonary fibrosis (IPF) – The need for early recognition and referral PRC-2128.

SYMPTOM CONTROL FOR ADVANCED RESPIRATORY DISEASE

Dr. Danny Galdermans Dept Respiratory Medicine ZNA Middelheim Antwerp

INTERSTITIAL LUNG DISEASE

IDIOPATHIC PULMONARY FIBROSIS

Management of Patients With Chronic Pulmonary Disease.

Chronic Obstructive Pulmonary Disease Natasha Chowdhury.

Idiopathic Pulmonary Fibrosis Standards of Care & Investigational Therapies Stephen K. Frankel, MD, FCCP Assistant Professor, Interstitial Lung Disease.

Pulmonary Fibrosis and Gradual Onset Breathlessness Dr. Tim Sutherland Consultant with a specialist interest in ILD.

PULMONARY FIBROSIS.

Chronic Obstructive Pulmonary Disease and Asthma: All That Wheezes? Clifford Courville, MD Pulmonary, Allergy, and Critical Care.

Pulmonary Rehabilitation In COPD

IDIOPATHIC PULMONARY FIBROSIS. TREATMENT IN IPF Treatments tried in IPF Antifibrotic Activity Anti-inflammatory Interferon-  1b Pirfenidone Endothelin.

BY MELISSA JAKUBOWSKI PULMONARY DISEASE TREATMENT CONCERNING COPD.

© 2013 Global Initiative for Chronic Obstructive Lung Disease

Living with Pulmonary Fibrosis Gerard Cox FIRH – SJHH McMaster University Sept 2013.

IDIOPATHIC PULMONARY FIBROSIS. BASICS in IPF CLASSIFICATION OF INTERSTITIAL LUNG DISEASE OR DIFFUSE PARENCHYMAL LUNG DISEASE.

End stage Lung Disease: What is it and what are some treatment options? NC Cardiopulmonary Rehabilitation Association Meeting March 14, 2014;

Interstitial Lung Disease MODULE G4 Chapter 28: pp

يکشنبه، 2015/10/11يکشنبه، 2015/10/11يکشنبه، 2015/10/11يکشنبه، 2015/10/11يکشنبه، 2015/10/11يکشنبه، 2015/10/11 بسم الله الرحمن الرحیم با سلام.

Esam H. Alhamad, M.D Assistant Professor of Medicine Consultant Pulmonary & Critical Care Medicine.

Idiopathic Pulmonary Fibrosis: Diagnosis and Understanding

GOLD Update 2011 Rabab A. El Wahsh, MD. Lecturer of Chest Diseases and Tuberculosis Minoufiya University REVISED 2011.

Chronic Obstructive Pulmonary Disease Austin Paul K.

OFEV ® (nintedanib) TOMORROW trial results Last updated These slides are provided by Boehringer Ingelheim for medical to medical education only.

PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =

PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =

PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =

PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =

PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =

R1 정수웅.  Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic, progressive, fibrosing interstitial pneumonia of unknown cause that occurs.

Restrictive lung disease

Chronic Obstructive Pulmonary Disease. COPD is an umbrella term for two diseases which cause progressive airflow obstruction Chronic Bronchitis- Inflammation.

Management of stable chronic obstructive pulmonary disease (2) Seminar Training Primary Care Asthma + COPD D.Anan Esmail.

Pulmonary Fibrosis - Support. Information Shortness of breath Fatigue Cough Financial Mood Future planning Pulmonary Fibrosis - Support.

A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis N ENGL J MED. May 18, /NEJMoa Talmadge E. King, Jr., M.D.,

Dr Julius Cairn. Introduction - update COPD Exacerbations Pulmonary rehabilitation Lung cancer - NSCLC Treatments for patients with limited lung function.

Clinical Tools for the Primary Care Physician. Objectives Raise the clinical index of suspicion for ILD in patients presenting with the hallmark signs.

A Controlled Trial of Sildenafil in Advanced Idiopathic Pulmonary Fibrosis The Idiopathic Pulmonary Fibrosis Clinical Research Network* N Engl J Med 2010.

Care | Valued | Excellence | Innovation Breathlessness Clinic: a non- pharmacological approach Julie Southon, Specialist Nurse Supportive and Palliative.

CHEST 2013; 144(1):234–240 R1 정수웅 Christopher J. Ryerson, MD ; Thomas Hartman, MD ; Brett M. Elicker, MD ; Brett Ley, MD ; Joyce S. Lee, MD ; Marta Abbritti,

Emerging Approaches to Treatment of IPF Gregory P. Cosgrove, MD Associate Professor, Pulmonary Division Assistant Director, Interstitial Lung Disease Program.

Acute Respiratory Failure: 5 types of Hypoxemia

Johnathan Grant D.O. FACOI

Introduction to Respiratory System

Objective 2 Discuss recent data, guidelines, and counseling points pertaining to the older adults with diabetes.

Anastasiia Raievska (Veramed)

Lung function in health and disease

Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease that is characterized by persistent respiratory symptoms and.

Prof Dr Guy JOOS Dept Respiratory Medicine Ghent University Hospital

Demystifying Idiopathic Pulmonary Fibrosis

Progressive Fibrosing Interstitial Lung Diseases – Addressing the Challenges Concept of Progressive Fibrosing ILDs With Examples.

831_ePAT CARE: Patient case Dr. Molina Dr

Patient with IPF and concomitant emphysema

Respiratory MCNs - Interstitial lung diseases

Patient Demographics Referred by:

Name: Age: Sex: Presenting History Symptom progression Current status:

Patient with FVC>90% predicted

Demographics of IPF in the USa-d

Interstitial lung disease

Diagnosi della BPCO 1.

How is pulmonary fibrosis diagnosed and monitored?

Treating Pulmonary Fibrosis

Change in forced vital capacity (FVC) % predicted (% pred) per week from baseline in the CAPACITY 004 and 006 study comparing pirfenidone (2403 mg·day−1)

New Models of Care in Idiopathic Pulmonary Fibrosis

KUMC Myotonic Dystrophy Day Pulmonary Treatments July 20, 2019

Endobronchial valve (EBV) treatment for emphysema, summary of treatment selection and outcome. Endobronchial valve (EBV) treatment for emphysema, summary.

Presentation transcript:

Management of Idiopathic Pulmonary Fibrosis in the Elderly Patient [ CHEST JULY 2015 ] 호흡기내과 R4. 박세정

How Should a Confident Diagnosis Be Made in the Elderly Patient? The American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association consensus statement (Am J Respir Crit Care Med, 2011) careful P/Ex (basilar crackles, digital clubbing) PFT (FVC ↓, TLC ↓, D LCO ↓) drug (amiodarone, MTX, nitrofurantoin…) connective tissue disease occupational or environmental exposures

What Is the Impact of Disease Complications and Comorbidities? comorbid disorders and complications associated with IPF in elderly patients : intrapulmonary : emphysema, pulmonary HTN, pulmonary embolism, CHF, primary lung cancer, chronic cough, acute exacerbation, pneumonia extrapulmonary : coronary artery disease, GERD, sleep-disordered breathing, anxiety and depression, deconditioning, frailty, osteoporosis, DM coexistent pulmonary fibrosis with emphysema (CPFE) pulmonary hypertension (PH) coronary artery disease (CAD) obstructive sleep apnea (OSA) gastroesophageal reflux disease (GERD)

What Are Key Considerations and Challenges for Disease Management in the Elderly Patient? f/u every 3-6 months PFT, 6MWT, oxygen titration walk study supplemental oxygen therapy pulmonary rehabilitation assessment of comorbidities that contribute to shortness of breath (ex. CAD, CHF)

What Are Current Treatment Considerations? corticosteroids cytotoxic drug immunosuppressive therapies (x) (cf. PANTHER-IPF) anticoagulation (x) antireflux medications NAC lung transplantation novel antifibrotic agents - ASCEND clinical trial : pirfenidone vs. placebo on FVC and PFS - CAPACITY trials : survival benefit - INPULSIS trials : nitedanib on FVC and risk of acute exaceration

What Are Important Prognostic Considerations? degree of fibrotic change on HRCT scan (: survival) changes in FVC, D LCO, and 6MWT distance (: risk of disease progression) need for supplemental oxygen (: risk of disease progression) all-cause and respiratory hospitalizations (: mortality) frailty specific gene polymorphisms statins or proton pump inhibitors biomarkers : matrix metalloproteinase-7, Krebs von den Lungen-6, surfactant proteins GAP (gender, age, lung physiology) index

How Can Patient-Centered Care and Personalized Management Be Provided? disease-centered model  patient-centered care model Evaluation for treatable disorders, such as cardiac disease and OSA Deconditioning through pulmonary rehabilitation Oxygen supplementation Emotional burdens

When and How Should Disease-Focused Therapies Be Transitioned to Supportive and Palliative Care? Symptom management and palliation Disease-centered approach with antifibrotic therapies and other intervention  palliative care with patient support and symptom control Pulmonary rehabilitation, supplemental oxygen use, cough suppression, counseling, psychosocial support, identification and treatment of comorbidities Respiratory failure : major cause of death (acknowledgement) End-of-life care

Summary The prevalence of IPF is highest in the population of affected patientswho are eldery Accurate and timely diagnosis Careful assessment of diease status Provision of disease-specific, supportive, and palliative care High index of suspicion for the presence of common comorbidities